4basebio PLC (LON:4BB – Get Free Report)’s stock price fell 4.1% on Friday . The company traded as low as GBX 1,180 ($14.73) and last traded at GBX 1,180 ($14.73). 12 shares traded hands during trading, a decline of 98% from the average session volume of 618 shares. The stock had previously closed at GBX 1,230 ($15.36).
4basebio Stock Down 4.1 %
The company has a market cap of £151.16 million, a P/E ratio of -1,512.82 and a beta of 1.09. The company’s 50-day moving average is GBX 1,228.32 and its two-hundred day moving average is GBX 1,335.21. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.
Insider Activity
In related news, insider Heikki Lanckriet acquired 46,500 shares of the business’s stock in a transaction on Friday, November 15th. The stock was acquired at an average cost of GBX 1,325 ($16.54) per share, with a total value of £616,125 ($769,290.80). Insiders own 68.44% of the company’s stock.
About 4basebio
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
Featured Stories
- Five stocks we like better than 4basebio
- What is the Euro STOXX 50 Index?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Financial Services Stocks Investing
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
